The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...

Integrated gene therapy successfully treated Haemophilia A in India, providing long-term relief without bleeding episodes for ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

Explore the investment prospects of 2seventy Bio, a spin-off from bluebird bio, in the competitive field of cell therapies ...

The Government of Kerala oversees the Kerala State Lotteries program. It was founded in 1967 and is the first of its kind in ...

Former Manila Mayor Isko Moreno Domagoso has channeled over P100 million from his talent fees to support various programs ...

Exciting potential in Korro Bio, Inc.'s non-viral gene editing platform as they enter clinical trials with a strong cash ...

Iowa has its first confirmed case of H5N1 bird flu in a poultry farm worker, the state's public health department announced.